Literature DB >> 2357264

Kinetics of the binding of mitoxantrone, ametantrone and analogues to DNA: relationship with binding mode and anti-tumour activity.

W A Denny1, L P Wakelin.   

Abstract

The kinetics of association and dissociation of DNA complexes of the anti-tumour agents mitoxantrone, ametantrone and related 1,4-bis(alkylamino)anthraquinones have been determined by stopped-flow spectrophotometry, in order to study relationships between structure, kinetic parameters and biological activity. Variations in the structure of the side chains of ametantrone analogues had little effect on the kinetic stability of the complexes, but the mitoxantrone complexes dissociated about an order of magnitude more slowly, suggesting an important role for the two hydroxyl groups on the chromophore of the latter compound. The results are consistent with other n.m.r. and molecular mechanics data, which suggest a binding model where the chromophore intercalates perpendicularly to the DNA base pair axis. Dissociation studies with DNA homopolymers of varying base composition suggest the kinetic mechanism is a mixed parallel/sequential one, with the slowest dissociation processes being from GC-rich sites in both homopolymers and natural DNA. The results suggest guidelines for the design of more tumour-active analogues of the class.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2357264

Source DB:  PubMed          Journal:  Anticancer Drug Des        ISSN: 0266-9536


  5 in total

Review 1.  Can anthracycline therapy for pediatric malignancies be less cardiotoxic?

Authors:  Joy M Fulbright; Winston Huh; Pete Anderson; Joya Chandra
Journal:  Curr Oncol Rep       Date:  2010-11       Impact factor: 5.075

Review 2.  Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent.

Authors:  L H Patterson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

3.  Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.

Authors:  Raushan T Kurmasheva; C Patrick Reynolds; Min H Kang; Cecilia Allievi; Peter J Houghton; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2013-10-26       Impact factor: 3.167

4.  AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo.

Authors:  S R McKeown; M V Hejmadi; I A McIntyre; J J McAleer; L H Patterson
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

5.  Synthesis, docking and biological activities of novel hybrids celecoxib and anthraquinone analogs as potent cytotoxic agents.

Authors:  Maha S Almutairi; Gehan H Hegazy; Mogedda E Haiba; Hamed I Ali; Nagy M Khalifa; Abd El-mohsen M Soliman
Journal:  Int J Mol Sci       Date:  2014-12-05       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.